A blockbuster batch of anti-obesity drugs is grabbing headlines and dominating social media posts, and never simply because the brand new 12 months fuels our resolve to shed kilos. The drugs — semaglutide (Vigovi), liraglutide (Sexanda), and tirzepetide (Zipbound) — are backed by science and anecdotal accounts of individuals losing as much as 20% of their body weight.
While that is noteworthy, it will not be the entire story. Many questions remain in regards to the drug, and a number of the answers are complicated.
what are they
The most up-to-date FDA-approved anti-obesity drugs are in a category called GLP-1 receptor agonists (GLP-1s). They mimic a hormone (glucagon-like peptide 1) that helps the body empty the stomach, control blood sugar levels, and suppress appetite, a mixture that results in weight reduction. One of the drugs, Zepbound, mimics GLP-1 in addition to a hormone called glucose-dependent insulinotropic polypeptide (GIP), which is believed to advertise the consequences of GLP-1.
The drugs also significantly reduce the chance of death from heart-related causes in people who find themselves obese or obese, in addition to those with heart disease (or each heart disease and diabetes, depending on the drug). In addition, they increase the power to exercise and enhance quality of life. “Drugs can also affect the reward center in the brain, the part that makes you want to eat chocolate cake even when you’re full. These drugs reduce the reward response, which can also reduce addictive behaviors like cravings for alcohol, sugar, and nicotine,” says Dr. Upwin.
Wait – aren’t those diabetes medications?
All three anti-obesity drugs were previously approved by the FDA just for the treatment of diabetes, under the brand names Ozempic, Victoza, and Monjaro.
But individuals who take them notice that they lose a number of weight. Studies confirmed this effect, and the FDA eventually approved the drug for weight reduction under latest brand names: Vigovi, Saxenda, and Zipbound. For obese or obesity, drugs are often prescribed in higher doses than their diabetic counterparts.
There are older GLP-1s approved for diabetes, equivalent to dulaglutide (Trulicity), but these treatments have little effect on weight.
How do you’re taking medicine?
Most of those latest drugs are available in the shape of injections that you simply give yourself every day or weekly. They are loaded into an injector pen (like an Epi pen for allergic reactions) that you simply press into your abdomen or thigh.
A tablet of Semaglutide (Rybelsus) can be available. It is FDA-approved for the treatment of diabetes, but not yet approved for weight reduction. Several other tablet formulations are being tested.
What are the uncomfortable side effects?
Both anti-obesity and anti-diabetic formulations have potential uncomfortable side effects. Common ones include fatigue, nausea, vomiting, or constipation. These go away after just a few weeks, says Dr. Upwin.
In rare cases, the drugs could cause small bowel obstruction, gastroparesis (stomach paralysis) or pancreatitis (inflammation of the pancreas).
“As far as I know, the side effects are not permanent. They go away if you stop taking the medication,” says Dr. Upwin. But the very long-term effects of taking the brand new drugs will not be yet known.”
Who is a drug candidate?
These drugs are only approved for weight reduction in people diagnosed with obesity (BMI of 30 or more) or obese (BMI of 27 to 29.9), plus a medical problem related to extra weight, equivalent to hypertension or high cholesterol. Of course, that hasn’t stopped some individuals who don’t meet those standards.
Because these drugs are latest and powerful, and the topic of intense study, it is anticipated that recommendations about their use will change in the approaching years. Researchers are more likely to discover latest groups of people that may profit – or, conversely, those that could also be at additional risk from the drug’s uncomfortable side effects.
How long do you’re taking the drug?
Taking considered one of the newer GLP-1s will not be a short-term solution. Once you’re taking the drug, you will need to stay on it indefinitely to get the advantages. If you stop taking the medication, chances are you’ll gain the burden back.
“Overweight and obesity, like diabetes and high blood pressure, are serious conditions that often require ongoing, even lifelong treatment. There is no ‘one-and-done’ cure,” says Dr. Upwin.
Costs and coverage
Amazing results don’t come low cost, and latest drugs range from about $900 to $1,600 per thirty days. Don’t expect your insurance to pay for them. Medicare doesn’t cover anti-obesity drugs, and depending in your plan, Medicare coverage for brand spanking new diabetes drugs is patchy and partial at best. Private insurance will often pay for diabetes medication, so long as you may have tried other diabetes treatments without success. But only 20% to 30% of personal insurers currently cover anti-obesity formulations, says Dr Upwin.
Some manufacturers of GLP-1s offer coupons with steep discounts, but many pharmacies don’t accept them. And watch out for budget-friendly versions advertised online or offered by “med-spas.” These are custom-mixed drugs imported from other countries, which haven’t any FDA oversight, and no guarantee of what they contain, says Dr. Upwin.
Are they even available?
To make matters worse, the drug’s rapid rise in popularity has now led to shortages, making them harder to search out. “The shortage has to do with manufacturers not anticipating this kind of demand,” says Dr Upwin. “More than 40% of Americans are obese. Drug companies didn’t anticipate how many of these people would want to use the drugs. Companies are scrambling to supply enough, according to us.”
Until they do, and until more insurance firms cover the drugs or manufacturers are forced to lower prices (each of that are being debated in Congress), many individuals are affected by serious medical conditions that must forgo probably the most effective anti-obesity drugs we have ever seen.
Photo: © CR/Getty Images